Details

Autor(en) / Beteiligte

• Orešič, Matej
• Posti, Jussi P.
• Kamstrup-Nielsen, Maja H.
• Takala, Riikka S.K.
• Lingsma, Hester F.
• Mattila, Ismo
• Jäntti, Sirkku
• Katila, Ari J.
• Carpenter, Keri L.H.
• Ala-Seppälä, Henna
• Kyllönen, Anna
• Maanpää, Henna-Riikka
• Tallus, Jussi
• Coles, Jonathan P.
• Heino, Iiro
• Frantzén, Janek
• Hutchinson, Peter J.
• Menon, David K.
• Tenovuo, Olli
• Hyötyläinen, Tuulia

Titel

Human Serum Metabolites Associate With Severity and Patient Outcomes in Traumatic Brain Injury

Ist Teil von

• EBioMedicine, 2016-10, Vol.12 (C), p.118-126

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2016

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Traumatic brain injury (TBI) is a major cause of death and disability worldwide, especially in children and young adults. TBI is an example of a medical condition where there are still major lacks in diagnostics and outcome prediction. Here we apply comprehensive metabolic profiling of serum samples from TBI patients and controls in two independent cohorts. The discovery study included 144 TBI patients, with the samples taken at the time of hospitalization. The patients were diagnosed as severe (sTBI; n=22), moderate (moTBI; n=14) or mild TBI (mTBI; n=108) according to Glasgow Coma Scale. The control group (n=28) comprised of acute orthopedic non-brain injuries. The validation study included sTBI (n=23), moTBI (n=7), mTBI (n=37) patients and controls (n=27). We show that two medium-chain fatty acids (decanoic and octanoic acids) and sugar derivatives including 2,3-bisphosphoglyceric acid are strongly associated with severity of TBI, and most of them are also detected at high concentrations in brain microdialysates of TBI patients. Based on metabolite concentrations from TBI patients at the time of hospitalization, an algorithm was developed that accurately predicted the patient outcomes (AUC=0.84 in validation cohort). Addition of the metabolites to the established clinical model (CRASH), comprising clinical and computed tomography data, significantly improved prediction of patient outcomes. The identified ‘TBI metabotype’ in serum, that may be indicative of disrupted blood-brain barrier, of protective physiological response and altered metabolism due to head trauma, offers a new avenue for the development of diagnostic and prognostic markers of broad spectrum of TBIs. [Display omitted] •The study reports that serum metabolites are sensitive to severity of TBI as well as predict the patient outcomes.•The findings are indicative of disruption in blood brain barrier and of protective response and altered TBI metabolism.•Metabolites significantly improved the prediction of patient outcomes when added to the established clinical model. Traumatic brain injury (TBI) is an example of a medical condition where there are still major lacks in diagnostics, outcome prediction, and the therapy development. Since the blood-brain barrier prevents diffusion of most water-soluble molecules with molecular mass over 500Da, here we hypothesized that circulating small molecules (metabolites) are a potential source of TBI markers. Based on serum metabolomic studies in two independent cohorts, we found that metabolites are sensitive to severity of TBI as well as predict the patient outcomes. The findings of this study may pave the way for new diagnostic tools for TBI.